Skip to main content

Table 1 Characteristics of women with endometrial cancer

From: Incidence and risk of venous thromboembolism according to primary treatment type in women with endometrial cancer: a population-based study

  The total follow-up period The first six months
VTE (−) VTE (+) Total   VTE (−) VTE (+) Total  
n = 25,899 (98.6%) n = 357 (1.4%) n = 26,256 (100%) P value n = 26,114 (99.5%) n = 142 (0.5%) n = 26,256 (100%) P value
Mean age (years), mean ± SE 54.17 ± 0.1 59.25 ± 0.6 54.24 ± 0.1 <.001 a 54.21 ± 0.1 58.35 ± 0.9 54.24 ± 0.1 <.001 a
SES, n (%)     0.101     0.61
 Mid- or high- SES 24,767 (95.6) 335 (93.8) 25,102 (95.6)   24,965 (95.6) 137 (96.5) 25,102 (95.6)  
 Low SES 1132 (4.4) 22 (6.2) 1154 (4.4)   1149 (4.4) 5 (3.5) 1154 (4.4)  
CCI, n (%)     <.001     0.695
 0 14,299 (55.2) 159 (44.5) 14,458 (55.1)   14,387 (55.1) 71 (50) 14,458 (55.1)  
 1 3464 (13.4) 48 (13.4) 3512 (13.4)   3491 (13.4) 21 (14.8) 3512 (13.4)  
 2 4688 (18.1) 76 (21.3) 4764 (18.1)   4738 (18.1) 26 (18.3) 4764 (18.1)  
 3 1366 (5.3) 24 (6.7) 1390 (5.3)   1381 (5.3) 9 (6.3) 1390 (5.3)  
 Over 4 2082 (8) 50 (14) 2132 (8.1)   2117 (8.1) 15 (10.6) 2132 (8.1)  
Year of endometrial cancer diagnosis, n (%)     0.101     0.016
 2009 1991 (7.7) 20 (5.6) 2011 (7.7)   2007 (7.7) 4 (2.8) 2011 (7.7)  
 2010 2099 (8.1) 25 (7) 2124 (8.1)   2116 (8.1) 8 (5.6) 2124 (8.1)  
 2011 2238 (8.6) 45 (12.6) 2283 (8.7)   2268 (8.7) 15 (10.6) 2283 (8.7)  
 2012 2319 (9) 32 (9) 2351 (9)   2342 (9) 9 (6.3) 2351 (9)  
 2013 2508 (9.7) 37 (10.4) 2545 (9.7)   2537 (9.7) 8 (5.6) 2545 (9.7)  
 2014 2553 (9.9) 38 (10.6) 2591 (9.9)   2583 (9.9) 8 (5.6) 2591 (9.9)  
 2015 2686 (10.4) 42 (11.8) 2728 (10.4)   2707 (10.4) 21 (14.8) 2728 (10.4)  
 2016 3081 (11.9) 47 (13.2) 3128 (11.9)   3106 (11.9) 22 (30) 3128 (11.9)  
 2017 3326 (12.8) 41 (11.5) 3367 (12.8)   3342 (12.8) 25 (17.6) 3367 (12.8)  
 2018 3098 (12) 30 (8.4) 3128 (11.9)   3106 (11.9) 22 (15.5) 3128 (11.9)  
Primary treatments b, n (%)     0.1     < 0.001
 No treatement c 5268 (20.3) 70 (19.6) 5338 (20.3)   5307 (20.3) 31 (20) 5338 (20.3)  
 Surgery d 17,386 (67.1) 231 (64.7) 17,617 (67.1)   17,509 (67.1) 108 (69.7) 17,617 (67.1)  
 Radiotherapy ± chemotherapy 544 (2.1) 6 (1.7) 550 (2.1)   546 (2.1) 4 (2.6) 550 (2.1)  
 Chemotherapy 723 (2.8) 18 (5) 741 (2.8)   729 (2.8) 12 (7.7) 741 (2.8)  
Hormone therapy 1978 (7.6) 32 (9) 2010 (7.7)   2010 (7.7) 0 (0) 2010 (7.7)  
Surgery, n (%)
 Total hysterectomy 9874 (56.8) 113 (48.9) 9987 (56.7) 0.016 9932 (56.7) 55 (50.9) 9987 (56.7) 0.225
 Radical hysterectomy 7512 (43.2) 118 (51.1) 7630 (43.3) 0.016 7577 (43.3) 53 (49.1) 7630 (43.3) 0.225
Radiotherapy, n (%)
 CCRT 16 (2.9) 1 (16.7) 17 (0) 0.172 e 17 (3.1) 0 (0) 17 (0) 1 e
 EBRT 306 (56.3) 5 (83.3) 311 (86.9) 0.24 e 308 (56.4) 3 (75) 311 (86.9) 0.637 e
 Brachytherapy 313 (57.5) 2 (33.3) 315 (37.4) 0.41 e 314 (57.5) 1 (25) 315 (37.4) 0.318 e
Chemotherapy, n (%)
 Platinum (cisplatin, carboplatin) 203 (48.2) 11 (61.1) 214 (48.7) 0.442 506 (69.6) 8 (66.7) 514 (69.6) 0.764 e
 Other agents 218 (51.8) 7 (38.9) 225 (51.3) 0.426 221 (30.4) 4 (33.3) 225 (30.4) 0.761 e
 Bevacizumab 16 (3.8) 0 (0) 16 (3.6) 1 e 16 (2.2) 0 (0) 16 (2.3) 1 e
Hormone therapy
 Progestins 1823 (74.6) 29 (72.5) 1852 (74.5) 0.736 e 1852 (74.5) 0 (0) 1852 (74.5) 1 e
 Tamoxifen 49 (2) 2 (5) 51 (2.1) 0.194 e 51 (2.1) 0 (0) 51 (2.1) 1 e
 Progestins and Tamoxifen 33 (1.3) 2 (5) 35 (1.4) 0.106 e 35 (1.4) 0 (0) 35 (1.4) 1 e
 Aromatase inhibitors 69 (2.8) 4 (10) 73 (2.9) 0.027 e 73 (2.9) 0 (0) 73 (2.9) 1 e
 Gonadotropin-releasing hormone agonists 21 (0.9) 1 (2.5) 22 (0.9) 0.299 e 22 (0.9) 0 (0) 22 (0.9) 1 e
 Levonorgestrel-releasing intrauterine system 450 (18.4) 2 (5) 452 (18.2) 0.027 452 (18.2) 0 (0) 452 (18.2) 1 e
Time between primary treatments and VTE diagnosis (days), mean ± SE   526.8 ± 46.4     79.9 ± 7.5   
  1. CCI Charlson comorbidity index; CCRT concurrent chemoradiation therapy; EBRT external beam radiation therapy; HIRA health insurance review & assessment Service; n number; SES socioeconomic status; VTE venous thromboembolism
  2. All values are expressed as mean ± standard error or number (%)
  3. a The Mann-Whitney U test was used for this analysis
  4. b Primary treatments refers to the first cancer treatments
  5. c Incidence of VTE after diagnosis of endometrial cancer was evaluated
  6. d Neoadjuvant chemotherapy followed by laparotomy or laparoscopy was considered as surgery
  7. e The Fisher’s exact test was used for this analysis
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us